T 100 - MAIA Biotechnology
Alternative Names: T-100 - MAIA BiotechnologiesLatest Information Update: 13 Apr 2023
At a glance
- Originator MAIA Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Apr 2023 Discontinued for Cancer in USA (unspecified route) (MAIA Biotechnology pipeline, August 2022)
- 05 Aug 2022 T 100 - MAIA Biotechnology is available for licensing as of 05 Aug 2022. https://maiabiotech.com/partners/
- 05 Aug 2022 Early research in Cancer in USA, as of August 2022 (unspecified route) (MAIA Biotechnology website, August 2022)